The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer

Meng Fen Wu, S. G. Hilsenbeck, Yee L. Tham, Rita Kramer, Richard M Elledge, J. C. Chang, L. C. Friedman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The aim of the study is to evaluate the efficacy of sertraline for controlling hot flashes in women with or at high risk of breast cancer. This was a randomized, double-blind, placebo-controlled study. All participants were asked to complete hot flash diaries. Participants reporting weekly hot flash scores >15 during baseline week underwent a 1-week single-blind placebo run-in. Those reporting hot flash score reductions >50% following placebo run-in were excluded. The remaining women received an assigned treatment for 4 weeks. Both groups' demographic and clinical characteristics were similar with a greater decline, but not statistically significant, in hot flash frequencies and scores in the sertraline-treated group compared with the placebo (P = 0.13 and P = 0.15, respectively). Emotional well-being improved significantly in the sertraline group (P = 0.041). The study failed to demonstrate effectiveness of sertraline in attenuating hot flashes in women with or at high risk of developing breast cancer who were not recommended to take hormone replacement therapy.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalBreast Cancer Research and Treatment
Volume118
Issue number2
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Hot Flashes
Sertraline
Breast Neoplasms
Placebos
Hormone Replacement Therapy
Demography

Keywords

  • Breast cancer
  • Hormone replacement therapy
  • Hot flashes
  • Selective serotonin reuptake inhibitor
  • Sertraline
  • Zoloft

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wu, M. F., Hilsenbeck, S. G., Tham, Y. L., Kramer, R., Elledge, R. M., Chang, J. C., & Friedman, L. C. (2009). The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Research and Treatment, 118(2), 369-375. https://doi.org/10.1007/s10549-009-0425-y

The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. / Wu, Meng Fen; Hilsenbeck, S. G.; Tham, Yee L.; Kramer, Rita; Elledge, Richard M; Chang, J. C.; Friedman, L. C.

In: Breast Cancer Research and Treatment, Vol. 118, No. 2, 11.2009, p. 369-375.

Research output: Contribution to journalArticle

Wu, Meng Fen ; Hilsenbeck, S. G. ; Tham, Yee L. ; Kramer, Rita ; Elledge, Richard M ; Chang, J. C. ; Friedman, L. C. / The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. In: Breast Cancer Research and Treatment. 2009 ; Vol. 118, No. 2. pp. 369-375.
@article{744883b01d4146baa9f5e55cb9a97311,
title = "The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer",
abstract = "The aim of the study is to evaluate the efficacy of sertraline for controlling hot flashes in women with or at high risk of breast cancer. This was a randomized, double-blind, placebo-controlled study. All participants were asked to complete hot flash diaries. Participants reporting weekly hot flash scores >15 during baseline week underwent a 1-week single-blind placebo run-in. Those reporting hot flash score reductions >50{\%} following placebo run-in were excluded. The remaining women received an assigned treatment for 4 weeks. Both groups' demographic and clinical characteristics were similar with a greater decline, but not statistically significant, in hot flash frequencies and scores in the sertraline-treated group compared with the placebo (P = 0.13 and P = 0.15, respectively). Emotional well-being improved significantly in the sertraline group (P = 0.041). The study failed to demonstrate effectiveness of sertraline in attenuating hot flashes in women with or at high risk of developing breast cancer who were not recommended to take hormone replacement therapy.",
keywords = "Breast cancer, Hormone replacement therapy, Hot flashes, Selective serotonin reuptake inhibitor, Sertraline, Zoloft",
author = "Wu, {Meng Fen} and Hilsenbeck, {S. G.} and Tham, {Yee L.} and Rita Kramer and Elledge, {Richard M} and Chang, {J. C.} and Friedman, {L. C.}",
year = "2009",
month = "11",
doi = "10.1007/s10549-009-0425-y",
language = "English (US)",
volume = "118",
pages = "369--375",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer

AU - Wu, Meng Fen

AU - Hilsenbeck, S. G.

AU - Tham, Yee L.

AU - Kramer, Rita

AU - Elledge, Richard M

AU - Chang, J. C.

AU - Friedman, L. C.

PY - 2009/11

Y1 - 2009/11

N2 - The aim of the study is to evaluate the efficacy of sertraline for controlling hot flashes in women with or at high risk of breast cancer. This was a randomized, double-blind, placebo-controlled study. All participants were asked to complete hot flash diaries. Participants reporting weekly hot flash scores >15 during baseline week underwent a 1-week single-blind placebo run-in. Those reporting hot flash score reductions >50% following placebo run-in were excluded. The remaining women received an assigned treatment for 4 weeks. Both groups' demographic and clinical characteristics were similar with a greater decline, but not statistically significant, in hot flash frequencies and scores in the sertraline-treated group compared with the placebo (P = 0.13 and P = 0.15, respectively). Emotional well-being improved significantly in the sertraline group (P = 0.041). The study failed to demonstrate effectiveness of sertraline in attenuating hot flashes in women with or at high risk of developing breast cancer who were not recommended to take hormone replacement therapy.

AB - The aim of the study is to evaluate the efficacy of sertraline for controlling hot flashes in women with or at high risk of breast cancer. This was a randomized, double-blind, placebo-controlled study. All participants were asked to complete hot flash diaries. Participants reporting weekly hot flash scores >15 during baseline week underwent a 1-week single-blind placebo run-in. Those reporting hot flash score reductions >50% following placebo run-in were excluded. The remaining women received an assigned treatment for 4 weeks. Both groups' demographic and clinical characteristics were similar with a greater decline, but not statistically significant, in hot flash frequencies and scores in the sertraline-treated group compared with the placebo (P = 0.13 and P = 0.15, respectively). Emotional well-being improved significantly in the sertraline group (P = 0.041). The study failed to demonstrate effectiveness of sertraline in attenuating hot flashes in women with or at high risk of developing breast cancer who were not recommended to take hormone replacement therapy.

KW - Breast cancer

KW - Hormone replacement therapy

KW - Hot flashes

KW - Selective serotonin reuptake inhibitor

KW - Sertraline

KW - Zoloft

UR - http://www.scopus.com/inward/record.url?scp=70350214276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350214276&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0425-y

DO - 10.1007/s10549-009-0425-y

M3 - Article

C2 - 19495957

AN - SCOPUS:70350214276

VL - 118

SP - 369

EP - 375

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -